Literature DB >> 16982896

Repression of IFN-gamma induction of class II transactivator: a role for PRDM1/Blimp-1 in regulation of cytokine signaling.

Reuben M Tooze1, Sophie Stephenson, Gina M Doody.   

Abstract

MHC class II is expressed in restricted lineages and is modulated in response to pathogens and inflammatory stimuli. This expression is controlled by MHC CIITA, which is transcribed from multiple promoters. Although factors required for induction of CIITA are well characterized, less is known about the mechanisms leading to repression of this gene. During plasma cell differentiation, B lymphocyte-induced maturation protein-1 (PRDM1/Blimp-1) represses promoter (p)III of CIITA, responsible for constitutive expression in B cells. pIV is inducible by IFN-gamma in epithelia, macrophages and B cells. An IFN regulatory factor-element (IRF-E) in CIITA-pIV, which is bound by IRF-1 and IRF-2, is necessary for this response. This site matches the PRDM1/Blimp-1 consensus binding site, and PRDM1/Blimp-1 is expressed in cell lineages in which this promoter is operative. We, therefore, investigated whether PRDM1 regulates CIITA-pIV and found that PRDM1 bound to CIITA-pIV in vivo and the IRF-E in vitro. PRDM1 repressed IFN-gamma-mediated induction of a CIITA-pIV luciferase reporter in a fashion dependent on an intact consensus sequence and competes with IRF-1/IRF-2 for binding to the IRF-E and promoter activation. In human myeloma cell lines that express IRFs, PRDM1 occupancy of CIITA-pIV was associated with resistance to IFN-gamma stimulation, while short interfering RNA knockdown of PRDM1 led to up-regulation of CIITA. Our data indicate that PRDM1 is a repressor of CIITA-pIV, identifying a target of particular relevance to macrophages and epithelia. These findings support a model in which PRDM1/Blimp-1 can modulate the cellular response to IFN-gamma by competing with IRF-1/IRF-2 dependent activation of target promoters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982896     DOI: 10.4049/jimmunol.177.7.4584

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression.

Authors:  Heike Schmidlin; Sean A Diehl; Maho Nagasawa; Ferenc A Scheeren; Remko Schotte; Christel H Uittenbogaart; Hergen Spits; Bianca Blom
Journal:  Blood       Date:  2008-06-13       Impact factor: 22.113

Review 2.  The generation of antibody-secreting plasma cells.

Authors:  Stephen L Nutt; Philip D Hodgkin; David M Tarlinton; Lynn M Corcoran
Journal:  Nat Rev Immunol       Date:  2015-02-20       Impact factor: 53.106

3.  Alternative splicing regulates Prdm1/Blimp-1 DNA binding activities and corepressor interactions.

Authors:  Marc A J Morgan; Arne W Mould; Li Li; Elizabeth J Robertson; Elizabeth K Bikoff
Journal:  Mol Cell Biol       Date:  2012-06-25       Impact factor: 4.272

4.  Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.

Authors:  Matthew A Smith; Gabriela Wright; Jian Wu; Prafullakumar Tailor; Keiko Ozato; Xianghong Chen; Sheng Wei; Janet F Piskurich; Jenny P-Y Ting; Kenneth L Wright
Journal:  J Biol Chem       Date:  2011-01-07       Impact factor: 5.157

5.  MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.

Authors:  Mojun Zhao; Frederick L Flynt; Mei Hong; Han Chen; Carolyn A Gilbert; Nicole T Briley; Sophia C Bolick; Kenneth L Wright; Janet F Piskurich
Journal:  Mol Immunol       Date:  2007-02-14       Impact factor: 4.407

6.  A System for In Vitro Generation of Mature Murine Plasma Cells Uncovers Differential Blimp-1/Prdm1 Promoter Usage.

Authors:  Emily Robinson; Matthew A Care; Kieran Walker; Michelle Campbell; Reuben M Tooze; Gina M Doody
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.422

7.  Blimp-1/PRDM1 mediates transcriptional suppression of the NLR gene NLRP12/Monarch-1.

Authors:  Christopher A Lord; David Savitsky; Raquel Sitcheran; Kathryn Calame; Jo Rae Wright; Jenny Pan-Yun Ting; Kristi L Williams
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.

Authors:  Kimberley Jade Anderson; Árný Björg Ósvaldsdóttir; Birgit Atzinger; Gunnhildur Ásta Traustadóttir; Kirstine Nolling Jensen; Aðalheiður Elín Lárusdóttir; Jón Thór Bergthórsson; Ingibjörg Hardardóttir; Erna Magnúsdóttir
Journal:  Oncogene       Date:  2020-06-12       Impact factor: 9.867

9.  Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.

Authors:  Kelly A Cycon; Kathleen Mulvaney; Lisa M Rimsza; Daniel Persky; Shawn P Murphy
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

10.  PRDM1 decreases sensitivity of human NK cells to IL2-induced cell expansion by directly repressing CD25 (IL2RA).

Authors:  Burcu Akman; Xiaozhou Hu; Xuxiang Liu; Tevfik Hatipoğlu; Hua You; Wing C Chan; Can Küçük
Journal:  J Leukoc Biol       Date:  2020-11-04       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.